Cheap Stock IPO Review: Build the Valuation Bridge
For controllers preparing an S-1, a cheap stock IPO review starts with a practical question: can you explain why the common-stock value used for recent option grants differs from the proposed offering price? You'll need a dated grant history, support for each valuation input and a reconciliation that separates later progress from information already available at grant.
The SEC staff may ask about unusual valuation movements. A low exercise price alone doesn't establish an accounting error, and an IPO price increase doesn't automatically make an earlier estimate wrong.
Key takeaway: Reconcile the underlying common-stock value to the offering price. Keep the exercise price and the option's fair value in separate columns.
What does a cheap stock IPO review actually test?
The issue is whether the earlier accounting valuation was supportable at its measurement date. SEC Financial Reporting Manual section 7520.1 identifies proximity to the offering, intervening events, restrictions, exercise dates and the company's financial condition as relevant factors. A common-stock value substantially below the IPO price should be reconcilable, but the guidance supplies no numerical trigger. SEC FRM Topic 7
Keep four amounts distinct:
- Exercise price: what the holder pays to exercise an option.
- Underlying common-stock value: a share-price input to the option valuation.
- Option fair value: the value of the award, calculated using its terms and applicable model assumptions.
- IPO offering price: the price offered to investors at a later date.
ASC 718 governs share-based compensation measurement. SAB Topic 14 explains the grant-date objective for equity awards and says that later value changes don't, by themselves, invalidate an originally reasonable estimate. The task is to test the original evidence, rather than substitute the eventual IPO outcome for everything management knew earlier. SEC SAB Topic 14, section C
Does a 409A valuation establish the ASC 718 value?
A 409A valuation addresses a tax question; it doesn't calculate option compensation cost. For the relevant nonstatutory-option exclusion from deferred-compensation treatment, Treasury's regulations require an exercise price at least equal to grant-date stock fair market value, together with other conditions. Statutory options have separate treatment. Treasury regulations in IRS Bulletin 2007-19
There is an accounting exception to the claim that tax valuations can never serve GAAP. FASB's October 25, 2021 ASU 2021-07 added a nonpublic-entity practical expedient for the current share-price input of equity-classified awards; a qualifying Treasury-regulation valuation can meet its reasonableness criteria. Liability-classified awards are excluded. FASB ASU 2021-07
The expedient still requires measurement-date support. A previous calculation must reflect later material information and cannot be more than 12 months old; the election applies to in-scope awards with the same underlying share and measurement date. Those conditions don't make the strike price the option's fair value. ASU 2021-07, added paragraphs 718-10-30-20C through 20H
IPO timing creates two separate checks. The tax regulations' illiquid-startup presumption is unavailable when an IPO can reasonably be anticipated within 180 days, but that restriction isn't a blanket ban on independent appraisals. Separately, SAB Topic 14's transition example treats the issuer as public at its initial registration filing, before trading; confirm the applicable ASC 718 scope and transition with the auditor rather than assuming private-company elections last until IPO day. IRS regulations, SAB Topic 14, section B
Which grants and events belong in the analysis?
Build a chronology that joins each grant to the information available on its measurement date. Start with the periods and issuances relevant to your registration statement and any staff question, then extend the history where it explains the valuation changes. Don't turn a convenient 12-month spreadsheet into a presumed SEC rule.
For each grant, record approval and communication dates, the accounting grant date, award quantity, strike, tax valuation date, GAAP share-price input, option-model value and vesting terms. Add split conversions and the amounts recorded in the financial statements so the schedule ties to the ledger.
Keep a separate event register with three fields: event date, date management knew the information, and affected assumption. A financing term sheet, a changed forecast or a board decision to pursue an IPO deserves a different entry from an investor meeting that happened months later.
PCAOB AS 2501 requires auditors to evaluate valuation methods, data and significant assumptions. Later transactions can provide evidence about an earlier estimate, but the auditor must consider intervening changes in conditions. That makes the distinction between earlier information and subsequent developments more than a drafting preference. PCAOB AS 2501, paragraphs .09 through .18 and .27 through .29
How do you bridge common-stock value to the IPO price?
Normalize the share basis, then quantify changes in assumptions and evidence. A bridge should show what changed, when it changed and why the change affects common-stock value. A sentence about “IPO progress” cannot explain the size of the gap.
The following is an illustrative scenario, not an issuer valuation or an accepted valuation model. All amounts use the same split-adjusted share basis, and scenario values already reflect the appropriate capital-structure allocation.
At a January grant, assume an IPO outcome worth $10 per common share and a remain-private outcome worth $4. With probabilities of 40% and 60%, respectively, and a simplified 20% marketability discount, the starting estimate is:
(40% × $10 + 60% × $4) × 80% = $5.12 per share.
| Sequential change | Increment per share | Running value |
|---|---|---|
| January estimate | Starting point | $5.12 |
| Increase IPO probability to 80%, holding scenario values and discount constant | $1.92 | $7.04 |
| Remove the illustrative 20% discount, holding other inputs constant | $1.76 | $8.80 |
| Later evidence changes IPO and private scenario values to $14 and $6 | $3.60 | $12.40 |
| Move from 80% IPO probability to the completed-IPO outcome | $1.60 | $14.00 |
| Later pricing evidence supports an $18 offering midpoint | $4.00 | $18.00 |
The increments total $12.88, taking $5.12 to $18.00. Their attribution depends on the sequence; real valuations can apply different discounts to different scenarios.
Each row needs dated evidence. The final $4 is an unresolved question until supported by specific pricing evidence, not a plug that becomes defensible because the table balances. Information known in January belongs in the January analysis.
Also test for double counting. If the IPO scenario already reflects preferred-stock conversion, don't add another conversion uplift; if you include new offering proceeds, include the corresponding new-share dilution.
This bridge stops at common-stock value. It doesn't produce option fair value or compensation expense, and subtracting the exercise price from the IPO midpoint isn't an option-valuation method. For the broader offering-pricing context, see Finrep's IPO valuation methods walkthrough.
What do Teknova and Sionna's SEC responses show?
The useful examples separate inputs and quantify assumptions, while leaving visible limits on what readers can reconstruct. Neither response establishes that every IPO receives a cheap-stock comment or that a particular response format guarantees acceptance.
Alpha Teknova's June 21, 2021 response addressed comment 9 from the staff's May 4 letter. It presented grant dates, exercise prices and accounting common-stock inputs before and after its June 17 forward split, against a $14 to $16 offering range. Teknova correspondence
Teknova explicitly distinguished a 409A valuation used to set an exercise price from the stock value used for compensation accounting. Its explanation also described a move from an option pricing method, or OPM, to a hybrid approach as IPO planning advanced; redacted accounting values and probabilities prevent a complete numerical reconstruction. Teknova response
Sionna Therapeutics' January 24, 2025 supplemental response addressed comment 16 from an October 10, 2024 letter. Its October 29 common-stock value was $7.07, compared with $5.53 on August 9; the October valuation assigned 25% to a near-term IPO, 25% to a base-case IPO and 50% to a trade sale. Sionna correspondence
Sionna disclosed that replacing the trade-sale weighting with equal weights on the two IPO scenarios would yield $10.11. That is a probability sensitivity, not the IPO midpoint: the preliminary offering range was redacted, and the letter's values preceded the anticipated reverse split. Sionna response
Borrow the analytical questions from these letters. Don't borrow their probabilities, discounts or explanations without company-specific support.
What belongs in the SEC response versus the prospectus?
A supplemental accounting analysis and public disclosure serve different purposes. FRM section 9520.2 says comments about unusual valuations seek analyses that help the staff evaluate accounting, rather than automatically requesting changes to MD&A or elsewhere in the prospectus. Section 9520.1 separately addresses methods, material assumptions, complexity and subjectivity in critical-estimate disclosure. SEC FRM Topic 9
Use this sequence to prepare the response:
- Put grant values and the offering range on the same share basis.
- Test whether each original input reflected information available at grant.
- Quantify supported subsequent changes and identify unexplained amounts.
- If an original input was wrong, recalculate the award valuation before writing a defense of it.
- Assess the resulting accounting and disclosure implications with the auditor and counsel, then answer the actual comment.
Public disclosure still needs its own assessment, including material known trends and uncertainties under section 9520.3. A strong supplemental memo doesn't replace the stock-compensation footnote; Finrep's ASC 718 disclosure checklist provides a companion starting point. SEC FRM Topic 9
What should the controller prepare before the next grant?
Make the next valuation review an evidence decision, not a calendar reminder. Send the valuation specialist a dated update covering forecasts, financing terms, IPO planning and other material developments, and ask which inputs require revision.
Assign finance the ledger tie-out, the specialist the valuation analysis, the auditor the accounting discussion and counsel the tax and response review. Keep the source document beside each bridge adjustment so a reviewer can follow the amount back to its evidence.
Before approval, resolve one question: does the proposed grant-date input reflect what the company knows today?
Frequently asked questions
Does a strike below the IPO price prove the accounting is wrong?
No. Those amounts answer different questions at different dates. Test the underlying-stock input and resulting option valuation against contemporaneous evidence.
Can one valuation support tax and accounting purposes?
It can when the applicable requirements are met. For an eligible nonpublic entity, the share-price practical expedient described above provides a specific route; it doesn't replace the option model.
Must every grant be revalued to the IPO midpoint?
No. The later midpoint is a comparison point, not an automatic replacement for a reasonable earlier grant-date estimate.
How should a stock split appear in the bridge?
Show the conversion explicitly and compare every per-share amount on one consistent basis. Convert award quantities too, so the grant register remains internally consistent.
What should an unexplained residual mean to the team?
It means the analysis has an open question. Find the evidence, revisit the input or revise the conclusion before calling the bridge complete.
